What was described last week by Roche Holding AG CEO Severin Schwan as a "chance for readouts" this year with anti-CD20 therapy Gazyva (obinutuzumab) came to pass in a big way, as Roche unit Genentech scored a phase III win in the indolent form of non-Hodgkin's lymphoma (NHL), a slow-growing type of the disease in which patients are prone to multiple relapses.